Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 5 (2008), Issue 6 (June)

1. Role of Bax in quercetin-induced apoptosis in human prostate cancer cells.
   Biochem Pharmacol, 75(12): 2345-55. [Abstract] [Full-text]
2. Recent trends in prostate cancer mortality show a continuous decrease in several countries.
   Int J Cancer, 123(2): 421-9. [Abstract] [Full-text]
3. Investigating Black-White differences in prostate cancer prognosis: A systematic review and meta-analysis.
   Int J Cancer, 123(2): 430-5. [Abstract] [Full-text]
4. Functional evidence implicating S100P in prostate cancer progression.
   Int J Cancer, 123(2): 330-9. [Abstract] [Full-text]
5. Dosimetric consequences of intrafraction prostate motion.
   Int J Radiat Oncol Biol Phys, 71(3): 801-12. [Abstract] [Full-text]
6. Quantification of prostate and seminal vesicle interfraction variation during IMRT.
   Int J Radiat Oncol Biol Phys, 71(3): 813-20. [Abstract] [Full-text]
7. Dose escalation for prostate cancer using the three-dimensional conformal dynamic arc technique: analysis of 542 consecutive patients.
   Int J Radiat Oncol Biol Phys, 71(3): 784-94. [Abstract] [Full-text]
8. Dose-volume parameters of the corpora cavernosa do not correlate with erectile dysfunction after external beam radiotherapy for prostate cancer: results from a dose-escalation trial.
   Int J Radiat Oncol Biol Phys, 71(3): 795-800. [Abstract] [Full-text]
9. Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study.
   Am J Surg Pathol, 32(6): 851-7. [Abstract] [Full-text]
10. Disparity between prostate tumor interior versus peripheral vasculature in response to verteporfin-mediated vascular-targeting therapy.
    Int J Cancer, 123(3): 695-701. [Abstract] [Full-text]
11. Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death.
    Int J Cancer, 123(3): 543-51. [Abstract] [Full-text]
12. Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men.
    Int J Cancer, 123(3): 647-52. [Abstract] [Full-text]
13. Haptoglobin-beta chain defined by monoclonal antibody RM2 as a novel serum marker for prostate cancer.
    Int J Cancer, 123(3): 633-40. [Abstract] [Full-text]
14. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells.
    Int J Cancer, 123(3): 552-60. [Abstract] [Full-text]
15. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.
    J Natl Cancer Inst, 100(11): 815-25. [Abstract] [Full-text]
16. Serum vitamin D concentration and prostate cancer risk: a nested case-control study.
    J Natl Cancer Inst, 100(11): 796-804. [Abstract] [Full-text]
17. The time gap between Pd-103 prostate brachytherapy and supplemental beam radiation does not impact on rectal morbidity or likelihood of cure.
    Am J Clin Oncol, 31(3): 231-6. [Abstract] [Full-text]
18. Metastatic prostate cancer mimicking primary osteosarcoma of the jaw: an infrequent clinical case.
    South Med J, 101(6): 657-9. [Abstract] [Full-text]
19. Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells.
    Oncogene, 27(25): 3596-604. [Abstract] [Full-text]
20. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
    Oncogene, 27(25): 3576-86. [Abstract] [Full-text]
21. Prostate cancer stem cells: a new target for therapy.
    J Clin Oncol, 26(17): 2862-70. [Abstract] [Full-text]
22. The role of SPINK1 in ETS rearrangement-negative prostate cancers.
    Cancer Cell, 13(6): 519-28. [Abstract] [Full-text]
23. Pulse sequence for dynamic volumetric imaging of hyperpolarized metabolic products.
    J Magn Reson, 193(1): 139-46. [Abstract] [Full-text]
24. Active surveillance for the management of prostate cancer in a contemporary cohort.
    Cancer, 112(12): 2664-70. [Abstract] [Full-text]
25. Using spectral moments of spiral networks based on PSA/mass spectra outcomes to derive quantitative proteome-disease relationships (QPDRs) and predicting prostate cancer.
    Biochem Biophys Res Commun, 372(2): 320-5. [Abstract] [Full-text]
26. Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor.
    Biochem Biophys Res Commun, 372(2): 356-61. [Abstract] [Full-text]
27. Reactions of potential jurors to a hypothetical malpractice suit: alleging failure to perform a prostate-specific antigen test.
    J Law Med Ethics, 36(2): 396-402, 214. [Abstract] [Full-text]
28. Racial differences in prostate cancer screening by family history.
    Ann Epidemiol, 18(7): 579-83. [Abstract] [Full-text]
29. Proteasome inhibitors induce apoptosis of prostate cancer cells by inducing nuclear translocation of IkappaBalpha.
    Arch Biochem Biophys, 475(2): 156-63. [Abstract] [Full-text]
30. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.
    JAMA, 299(23): 2760-9. [Abstract] [Full-text]
31. Association between polymorphisms of folate-metabolizing enzymes and risk of prostate cancer.
    Eur J Surg Oncol, 34(7): 805-10. [Abstract] [Full-text]
32. Comparative study of experienced vs non-experienced radiologists in assessing parametric CT images of the response of the prostate gland to radiotherapy.
    Br J Radiol, 81(967): 572-6. [Abstract] [Full-text]
33. Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules.
    Br J Radiol, 81(967): 549-63. [Abstract] [Full-text]
34. Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention.
    Proc Natl Acad Sci U S A, 105(24): 8369-74. [Abstract] [Full-text]
35. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial.
    J Immunother, 31(6): 577-85. [Abstract] [Full-text]
36. Inhibition of Ca2+-independent phospholipase A2 decreases prostate cancer cell growth by p53-dependent and independent mechanisms.
    J Pharmacol Exp Ther, 326(1): 59-68. [Abstract] [Full-text]
37. Robotic salvage retropubic prostatectomy after radiation/brachytherapy: initial results.
    BJU Int, 102(1): 93-6. [Abstract] [Full-text]
38. Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy.
    BJU Int, 102(1): 28-32. [Abstract] [Full-text]
39. Accuracy of life tables in predicting overall survival in patients after radical prostatectomy.
    BJU Int, 102(1): 33-8. [Abstract] [Full-text]
40. Clinical and pathological features of screen vs non-screen-detected prostate cancers: is there a difference?
    BJU Int, 102(1): 24-7. [Abstract] [Full-text]
41. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
    BJU Int, 102(1): 44-7. [Abstract] [Full-text]
42. Effect of extracellular ATP on the growth of hormone-refractory prostate cancer in vivo.
    BJU Int, 102(1): 108-12. [Abstract] [Full-text]
43. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
    BJU Int, 102(1): 39-43. [Abstract] [Full-text]
44. Occupational physical activity in relation with prostate cancer and benign prostatic hyperplasia.
    Eur J Cancer Prev, 17(4): 336-9. [Abstract] [Full-text]
45. High prostate cancer mortality in Norway evaluated by automated classification of medical entities.
    Eur J Cancer Prev, 17(4): 331-5. [Abstract] [Full-text]
46. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.
    J Clin Oncol, 26(18): 2979-83. [Abstract] [Full-text]
47. Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer.
    J Clin Oncol, 26(18): 2973-8. [Abstract] [Full-text]
48. Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.
    J Clin Oncol, 26(18): 2959-65. [Abstract] [Full-text]
49. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer.
    J Control Release, 129(2): 107-16. [Abstract] [Full-text]
50. The influence of a dietary protocol on cone beam CT-guided radiotherapy for prostate cancer patients.
    Int J Radiat Oncol Biol Phys, 71(4): 1279-86. [Abstract] [Full-text]
51. TIP30 is associated with progression and metastasis of prostate cancer.
    Int J Cancer, 123(4): 810-6. [Abstract] [Full-text]
52. Legume and isoflavone intake and prostate cancer risk: The Multiethnic Cohort Study.
    Int J Cancer, 123(4): 927-32. [Abstract] [Full-text]
53. Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype.
    Int J Cancer, 123(4): 760-8. [Abstract] [Full-text]
54. P53 mutations in stromal fibroblasts sensitize tumors against chemotherapy.
    Int J Cancer, 123(4): 967-71. [Abstract] [Full-text]
55. Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies.
    Int J Cancer, 123(4): 899-904. [Abstract] [Full-text]
56. Selecting patients for exclusive permanent implant prostate brachytherapy: the experience of the Paris Institut Curie/Cochin Hospital/Necker Hospital group on 809 patients.
    Int J Radiat Oncol Biol Phys, 71(4): 1042-8. [Abstract] [Full-text]
57. The effect of changing technique, dose, and PTV margin on therapeutic ratio during prostate radiotherapy.
    Int J Radiat Oncol Biol Phys, 71(4): 1057-64. [Abstract] [Full-text]
58. Phase I-II study of intraoperative radiation therapy (IORT) after radical prostatectomy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 71(4): 1049-56. [Abstract] [Full-text]
59. Observations on real-time prostate gland motion using electromagnetic tracking.
    Int J Radiat Oncol Biol Phys, 71(4): 1084-90. [Abstract] [Full-text]
60. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes.
    Int J Radiat Oncol Biol Phys, 71(4): 1028-33. [Abstract] [Full-text]
61. Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: planning procedures and early experiences.
    Int J Radiat Oncol Biol Phys, 71(4): 1034-41. [Abstract] [Full-text]
62. Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT.
    Int J Radiat Oncol Biol Phys, 71(4): 1065-73. [Abstract] [Full-text]
63. Inter- and intrafractional movement-induced dose reduction of prostate target volume in proton beam treatment.
    Int J Radiat Oncol Biol Phys, 71(4): 1091-102. [Abstract] [Full-text]
64. Stereographic targeting in prostate radiotherapy: speed and precision by daily automatic positioning corrections using kilovoltage/megavoltage image pairs.
    Int J Radiat Oncol Biol Phys, 71(4): 1074-83. [Abstract] [Full-text]
65. Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway.
    Oncogene, 27(28): 3986-98. [Abstract] [Full-text]
66. Dietary n-3 polyunsaturated fatty acids enhance hormone ablation therapy in androgen-dependent prostate cancer.
    Am J Pathol, 173(1): 229-41. [Abstract] [Full-text]
67. Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases.
    Urol Int, 80(4): 448-50. [Abstract] [Full-text]
68. Prevalence of prostate cancer in end-stage renal disease patients.
    Urol Int, 80(4): 419-24. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.